Precigen, Inc. (PGEN)
NASDAQ • Healthcare
Last close at September 9, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Precigen, Inc. keeps $37 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 12
in 63 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Precigen’s results for the second fiscal quarter of 2026 pointed to cash outflow and a small share repurchase, with next-period consensus calling for EPS of $0.09 on revenue of $69.2 million; the company reported the quarter on August 4, 2026. During the period, operating cash flow was negative at roughly $17.8 million, reflecting a net cash use from operations. The company also repurchased about $1.5 million of stock. Precigen operates across human therapeutics and enabling technologies, including platforms such as UltraVector, RheoSwitch, and ActoBiotics, alongside regenerative-medicine and reproductive-tool offerings such as genetically engineered swine and reproductive and embryo transfer technologies.
About Precigen, Inc.
Precigen, Inc. is a small-cap Biotechnology company listed on the NASDAQ under the ticker PGEN. The company develops disease-modifying treatments and applies its platform technologies to regenerative medicine and reproductive tools, with operations rooted in a business founded in 1998 and based in Germantown, Maryland.
Today's Snapshot
PGEN ended yesterday 1.0% down at 6.80.
Trading Volume
Below 10d avg (3.5M)
3.1M
vs S&P 500 Today
Underperforming Market
-0.54%
Updated: September 10, 2026 at 12:14 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$4.97 - $6.98Buy
- RSI (14)50.93Neutral
- Stochastic %K (14, 3, 3)32.35Neutral
- MACD Level (12, 26)0.19Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.